Machine learning prediction of pediatric adverse drug reactions using consensus-derived scarce data
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces a novel computational method to improve pediatric drug safety by identifying adverse drug reactions (ADRs) in children. The approach enhances pharmacovigilance, addressing critical data gaps in pediatric medicine.
Area Of Science
- Pharmacovigilance
- Computational Toxicology
- Pediatric Pharmacology
Background
- Adverse drug reactions (ADRs) are a major cause of illness and death in children, who have unique developmental vulnerabilities.
- Pediatric drug safety research faces challenges due to limited data and reliance on adult-focused studies, creating significant evidence gaps.
Purpose Of The Study
- To develop and validate a comprehensive computational approach for pediatric pharmacovigilance.
- To improve the identification of pediatric-specific adverse drug reactions (ADRs) and bridge existing evidence gaps.
Main Methods
- Integrated consensus-driven signal detection, multi-level biological features, and interpretable machine learning (XGBoost).
- Utilized 1.4 million FDA Adverse Event Reporting System reports to create the largest pediatric drug-ADR dataset.
- Employed severity-specific thresholds and voting across four algorithms (PRR, ROR, BCPNN, EBGM) for optimized ADR identification.
Main Results
- The computational approach achieved a significant predictive performance (ROC AUC: 0.7177), particularly for imbalanced datasets.
- Cross-domain analysis confirmed that adult-derived models poorly generalize to pediatric populations.
- Identified both known and novel pediatric-specific ADRs supported by existing literature.
Conclusions
- The developed computational framework offers methodological innovation for pediatric pharmacovigilance.
- This work addresses a critical need for improved drug safety data in pediatric populations.
- The findings provide practical tools for clinical and regulatory decision-making in pediatric drug safety.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...